Table 2 Patients comparison based on the presence or absence of ≥ 40% PPG > 160 mg/dL
Patients with at least 40% PPG measurements > 160 mg/dL | No (N = 38) | Yes (N = 55) | P-value |
|---|---|---|---|
Sex (male/female) | 19/19 (50.0/50.0%) | 33/19 (60.0/50.0%) | 0.3982 (a) |
Age (years) | 65.0 (10.8) | 64.0 (10.6) | 0.6776 (b) |
BMI (kg/m2) | 30.1 (6.0) | 29.7 (4.6) | 0.7069 (b) |
Systolic blood pressure (mmHg) | 140.1 (16.3) | 137.7 (15.2) | 0.4653 (b) |
Diastolic blood pressure (mmHg) | 79.9 (9.5) | 76.6 (8.8) | 0.0885 (b) |
Total cholesterol (mg/dL) | 166.2 (32.5) | 163.6 (30.8) | 0.7034 (b) |
Triglycerides (mg/dL) | 148.0 (90.2) | 153.7 (101.5) | 0.7816 (b) |
LDL cholesterol (mg/dL) | 88.8 (34.1) | 91.8 (27.8) | 0.6394 (b) |
HDL colesterol (mg/dL) | 51.7 (19.6) | 43.8 (11.5) | 0.0318 (b) |
Time since diagnosis (years) | 14.5 (8.9) | 17.3 (8.0) | 0.1231 (b) |
≤ 2 years | 3 (7.9%) | 0 (0.0%) | 0.0302 (c) |
2.1 to 5 years | 3 (7.9%) | 2 (3.6%) | |
5.1 to 10 years | 6 (15.8%) | 8 (14.5%) | |
> 10 years | 26 (68.4%) | 45 (81.8%) | |
HbA1c (%) | 7.8 (0.5) | 8.0 (0.5) | 0.0912 (b) |
HbA1c (mmol/mol) | 62 (5) | 64 (5) | |
Treatment with basal insulin: final dose (units/day) | 31.1 (16.1) | 31.1 (17.6) | 0.9869 (a) |
Years of treatment | 5.0 (4.7) | 5.6 (4.4) | 0.5474 (b) |
Treatment with ADO | 33 (86.8%) | 49 (89.1%) | 0.7543 (a) |
Years of treatment | 9.2 (7.5) | 11.7 (7.1) | 0.1283 (b) |
Treatment with metformin | 30 (78.9%) | 45 (81.8%) | 0.7927 (a) |
Years of treatment | 9.8 (7.6) | 10.4 (6.6) | 0.7361 (b) |
Treatment with DPP-4 Inhibitor | 8 (21.1%) | 20 (36.4%) | 0.1673 (a) |
Years of treatment | 1.9 (1.5) | 2.6 (1.8) | 0.2983 (b) |
Treatment with sulfonylurea | 8 (21.1%) | 21 (38.2%) | 0.1110 (a) |
Years of treatment | 6.7 (4.9) | 12.7 (7.2) | 0.0379 (b) |